Key facts
- Anaxiom’s last known valuation is $18.0M (Apr 2025).
- It has raised $16.5M across 4 recorded rounds; the latest was Early Stage VC ($5.4M) in Apr 2025.
- Notable investors include Fjord Ventures.
- Anaxiom has filed 4 Form Ds with the SEC since 2016, most recently Apr 2025 ($5.4M sold to 9 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Anaxiom
Funding rounds
4 roundsAbout Anaxiom
Developer of implantable medical device technology designed for obesity treatment. The company develops minimally invasive systems that selectively modulate blood flow through a percutaneous, catheter-based approach, incorporating implantable components engineered for controlled physiological response, clinical compatibility, and procedural integration with existing interventional techniques, enabling healthcare providers and medical institutions to address chronic obesity by supporting sustained weight management while reducing reliance on invasive surgical interventions.
- Sector
- Healthcare
- HQ
- Laguna Hills, CA, United States
- Founded
- 2013
- Website
- anaxiomcorp.com/
- Ownership
- Privately Held (backing)
Anaxiom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anaxiom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anaxiom in its N-PORT filings yet. We sweep new filings monthly.